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Purpose: To determine the therapeutic efficacy of a novel rare sugar, L-psicose, for the treatment of HSV-1
induced herpetic stromal keratitis (HSK) in a mouse eye model.
Methods: One rare sugar L-psicose was assayed for HSV-1 inhibition of in vitro virus adsorption. The IC50
and IC90 values of L-psicose were determined using plaque reduction assay (PRA) in CV-1 cell. Female
Balb/c mice were corneally infected with HSV-1, strain KOS-GFP; A topical eye drop treatment of L-psi-
cose was started 24 h after infection and continued four times daily for ten consecutive days. The severity
of HSK was monitored by slit lamp examination in a masked fashion and Infectious HSV-1 shedding was
determined by PRA.
Results: L-psicose was found to have anti-viral activity in vitro at an IC50 dose of 99.5 mM and an IC90 dose
of 160 mM. Topical eye drop treatment with 200 mM L-psicose in PBS solution significantly reduced the
severity of HSK compared to the mock treatment group. The in vivo mouse ocular model results of L-
psicose therapy correlated with accelerated clearance of virus from eye swabs.
Conclusion: The results suggest that topical treatment with rare sugar L-psicose has efficacy against HSK
through inhibition of HSV-1.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Monosaccharides are essential component of cell surface re-
ceptors and play a very important role in cell signaling pathways
(1). As a result, carbohydrates that can disrupt binding of molecules
to the cell surface receptors or interrupt cell-signaling pathways
may have important therapeutic potentials (2).
On the basis of availability we can classify monosaccharide into
two groups, natural and rare. According to International Society of
Rare Sugars (ISRS) rare sugars are monosaccharides and their
derivatives that rarely exist in the nature. The practical application
or usefulness of rare carbohydrates has not been well investigated
because of high costs and unavailability. However, because of the
recent introduction of “Izumoring” schemes (3) it is now possible
to produce many of these rare monosaccharides in large quanti-
ties by using microbial and enzymatic transformations. As a result,
functional studies of rare sugars have gained momentum in recent
years. Utilization of rare sugars for various purposes still awaits
extensive exploration. Despite their costs and low availability,
these rare carbohydrates are very important since they have the
potential for use in many areas such as food additives, diet sugars,
antioxidants, antiviral agents, nucleoside analogs, glycosidase in-
hibitors, and anticancer agents (4e11). In a previous study
Muniruzzaman et al found that some simple rare ketoses (L-
Xylulose and L-Fructose) were specific inhibitors of alpha-
glucosidase and glucosidase in vitro and in vivo (4). This study
also reported that some rare sugars inhibited the removal of
glucoses from N-linked oligosaccharides of the influenza viral
hemagglutinin in the cell culture systems. Activities of glucosi-
dases are required for the right processing of glycoproteins so that
correct folding and sorting can be maintained (12). Our knowl-
edge about the physiological effects of rare carbohydrates is very
limited. In a previous study, since some rare keto-sugars appear to
be inhibitory to glycoprotein processing enzymes (4), it was of
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interest to screen ketohexoses to determine whether any of them
would inhibit the entry of HSV1 to cell. Among the eight keto-
hexoses D-tagatose, L-tagatose, D-psicose, L-psicose, D-sorbose
and L-fructose are considered to be rare as they are found in na-
ture very low quantities. We screened all these ketohexoses
(Fig. 1) in vitro for their anti-HSV-1 activity and found L-psicose to
have relatively strong activity. In the present study, we show that
L-psicose is effective in inhibiting HSV-1 in vitro. The mechanism
of HSV-1 inhibition by L-psicose is mediated through blocking of
viral adsorption to cell surface. We also show that in vivo, L-psi-
cose is effective in inhibiting HSV-1 induced corneal opacity and
ocular virus shedding in mouse eye model.
2. Materials and methods
2.1. Antiviral compounds
All ketohexoses used in this study was produced in Dr. Izomuri's
lab. Anti-viral peptide apoEdp was commercially synthesized
(GeneMed, Texas, US) and used as described before (13). ApoEdp is
a short 18 aa peptide derived from receptor binding region of hu-
man apolipoprotein E effectively inhibits HSV-1 adsorption in vitro
and herpetic stromal keratitis (HSK) in vivo (13).
2.2. Cells, viruses and treatment
CV-1 cells (African green monkey kidney cells) were purchased
from American Type Culture Collection, Manassas, VA) were
propagated in Eagle's minimum essential medium (EMEM) con-
taining 0.15% Na2CO3 supplemented with 10% fetal bovine serum
(FBS), penicillin G (100 U/ml), and streptomycin (100 mg/ml).
HSV-1 strain KOS-GFP (gift from Timothy P Foster, LSU Health
Sciences Center, New Orleans, LA, USA) was used and titrated in
CV-1 cells.
2.3. Virus adsorption assay
CV-1 cells prepared with a final density of 4  106 cells/mL
added with HSV-1 KOS-GFP at 1 PFU (Plaque forming Units)/cell
and varying concentrations of L-psicose was incubated at 4 C for
1 h to allow adsorption but to prevent penetration. Following
adsorption, unbound virus and sugar was removed by washing
three times with cold PBS (4 C). Cell pellets were serially diluted
and plated on 24-well monolayer of CV-1 cells with an overlay of
0.5% methylcellulose. Following 48 h of incubation at 37 C, cells
were then fixed with 5% buffered formalin (5% formalin in PBS) and
stained with 0.05% crystal violet. Positive control well did contain
apoEdp peptide and performed in parallel. The number of HSV-1
infected plaques was counted for each concentration of L-psicose
or peptide and for no drug controls. The inhibitory effect of the L-
psicose on plaque reduction was calculated by following formula.
Percentage inhibition (number) ¼ (1 e plaque number in antiviral
well/plaque number in no drug control well)  100. The 50% and
90% dose of inhibitory concentration was hand calculated from the
dose response curves generated from the data (14). For each
experiment, three independent replicates were performed.
2.4. Mice
For the animal experiment, Xavier University of Louisiana
Institutional Animal Care and Use Committee approved procedure
was followed. We used female C57BL/6 (Taconic Farms, NY) from 5
to 6 weeks of age.
2.5. Ocular infection
Mice were anesthetized using a mixture of Xylazine (6.6 mg/kg
of body weight) and Ketamine (100 mg/kg) through intraperitoneal
route of injection. Scarification of eyes was performed in a 2X2
Fig. 1. Structure of eight ketohexoses screened in this study for anti-HSV-1 activity.
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cross-hatch pattern and then 4 mL of virus was inoculated in each
eye containing 5  105 PFU of virus/inoculum.
2.6. Quantification of viral titer from eye swabs
Eye swabs were collected to perform plaque assays to quantify
the virus using CV-1 as indicator cell. Sterile filter paper strips were
used as eye swabs and mixed with I ml of cold EMEM containing
10% FBS. Serial dilution of eye swabs was done before adding on CV-
1 cell monolayer and incubated at 37 C for 1 h for virus adsorption.
Following adsorption, medium was aspirated and fresh EMEM was
added to each well. After 2 days, viral plaques were counted in each
well for quantification of PFU/mL.
2.7. Treatment groups
Safety and toxicity of L-psicose was done in the eyes of naïve
mice. The 200 mM concentration of L-psicose was well tolerated
without any corneal toxicity when applied five times a day for ten
consecutive days. Corneal opacity and neovascularization were
evaluated as a measure of toxicity. One day after corneal infection
with virus, mice were tropically treated with 4 mL of 200 mM L-
psicose in each eye. Placebo was applied with PBS for mock-
treatment groups.
2.8. Slit lamp examination and quantitation of corneal opacity and
neovascularization
Mice eyes were examined under a slit lamp microscope (Eye
Cap; Haag-Streit International, Mason OH, USA) in a masked
fashion. Severity of the HSK infection was determined by
measuring corneal opacity (13). Corneal opacity was evaluated on a
parameter as follows: 0, no opacity; 1, mild cloudiness with visible
iris; 2, moderate cloudiness with obscured iris; 3, total corneal
cloudiness with invisible iris; 4, total opacity with no posterior
view.
2.9. Statistics
The potentiality of the sugar and peptide for treatment against
HSV-1 induced corneal opacity and HSV-1 titer in the eyes were
determined by the mean ± SEM and considered significant at P
values <0.05, calculated with students t-test.
3. Results
3.1. L-Psicose inhibits HSV-1 adsorption in CV-1 cells
Effect of L-psicose against HSV-1 adsorption was evaluated in
CV-1 cells. The IC50 and IC90 dose of inhibition was calculated as
described by others (14). L-psicose was found to have anti-HSV-1
activity at an IC50 dose of 99.51 mM and IC90 dose of 166.48 mM
(Table 1). As a positive control drug, we used a peptide (apoEdp)
previously reported by us to have peptidomimetic blocking effect
on HSV-1 adsorption (13).
3.2. Eye drop treatment of L-psicose inhibits corneal opacity
induced by HSV-1
Starting at day 1 post-infection, topical eye drop treatment of
200 mM L-psicose applied 4 mL per eye, 4 times a day for 10
consecutive days. Corneal opacity was measured by slit lamp ex-
amination and the severity was graded as described in the mate-
rials and methods. Corneal opacity was not evident until day 14
post-infection. As evident in Fig. 2, L-psicose treatment resulted
significant (p < 0.05) inhibition of corneal opacity compared to
mock treated eyes.
3.3. Eye drop treatment of L-psicose inhibits infectious HSV-1
shedding
Ocular swabs were assayed to determine the antiviral effect of L-
psicose eye drop treatment. Infectious virus shedding was calcu-
lated by determining PFU/mL. Shedding of infectious virus from L-
psicose treated eyes were found significantly (p < 0.05) reduced
compared to mock-treated (Fig. 3).
4. Discussion
Current drug discovery efforts for HSV focus primarily on
nucleoside based inhibition of viral genome synthesis. However,
drug-resistant mutations in the viral genome can arise during
therapy and, subsequently, reduce the effectiveness of specific viral
enzyme inhibitors. Unfortunately, incorporation of anti-metabolite
(nucleoside analog) often reported to get incorporated into DNA of
normal host cells that may lead to the development of toxicity
during topical and systemic therapy (15).Herpes infections continue
to be prevalent and resistance to nucleoside analogs has been re-
ported (16, 17), especially in immunocompromised transplant re-
cipients and AIDS patients. Therefore, it is important to explore new
treatment options with alternative mechanisms of antiviral action
(18). An alternative and complementary strategy is to target the
cellular receptors that are also required for viral attachment
(adsorption), entry, and cell-to-cell spread. We focused on virus
adsorption to susceptible CV-1 cells, which is an early stage rather
than late stage of penetration and intracellular replication of virus
life cycle. As a positive control for virus adsorption assay we used a
peptide called apoEdp previously reported by us (13) antiviral
through peptidomimetic inhibition of early stage HSV-1 replication.
Acyclovir (ACV) is a common choice of nucleoside-based treatment
ofHSV-1 infection. Our rationale of not to useACVas positive control
becauseACVas a nucleoside analog inhibits late stage of viral nucleic
acid synthesis but not early stage of virus adsorption.
Initially, in this study we have screened eight ketohexoses
(Fig. 1) in vitro for their anti-HSV-1 activity using plaque reduction
assay. Among the eight ketohexoses L-psicose has the maximum
inhibitory effect followed by L-fructose (data not shown). The
mechanism of HSV-1 inhibition by these two rare ketohexoses is
mediated through the blocking of viral adsorption to the cell sur-
face. Fig. 1 shows the structural formula of the eight ketohexoses.
One interesting observation here is that the two active ketohexoses
(L-psicose and L-fructose) has structural similarity at the carbon
number 4 and 5. We hypothesize that position of hydroxyl group at
carbon number 3, 4 and 5 is important for anti-HSV-1 activity.
Based on our observation, we predict that ketopentose L-ribulose
may show similar anti-HSV-1 activity because of it's structural
similarity to L-psicose and L-fructose.
This is our initial study regarding anti-HSV-1 activity of rare
monosaccharide L-psicose. Very little is known about the biological
function of this rare ketohexose. We have done cell viability testing
in Vero (CV-1) cells using a dye reduction assay. L-psicose appeared
Table 1
L-psicose inhibits HSV-1 adsorption to CV-1 cell.
Methods Criteria L-psicose(mM) ApoEdp peptide (mM)
Adsorption IC50 99.51 0.4
IC90 166.48 0.55
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to be non-toxic at the maximum concentration used in this study.
However, further studies needed to be done to reduce the IC50/IC90
of L-psicose. HSK evident through appearance of stromal opacity in
the cornea is the result of virus replication inside the cell and
subsequent invasion of immune cells in the stroma resulting
corneal cloudiness or opacity. Topical eye drop treatment dose of L-
psicose was chosen 200 mM which is higher than IC90 (167 mM)
but found safe and nontoxic to naïve mice eyes. Our experimental
data of corneal opacity and infectious virus shedding suggest that L-
psicose treatment results inhibition of virus entry and lower load of
virus inside the cell may have diminished infectious virus shedding
and development of less severe corneal opacity.
Studies regarding structural and functional impact of carbohy-
drates are very important
in the development of carbohydrate-based drugs. During the last
two decades, several
imino sugars and nucleotide analogs with antiviral properties have
been reported (19e22). However, to our knowledge this report is
the first report of a simple sugar with in
vitro and in vivo antiviral property.
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Fig. 2. Female C57Bl/6 mice were corneally infected with HSV-1 KOS-GFP. Topical eye drop treatment with 200 mM solution of L-psicose in PBS started next day after corneal
inoculation of virus. Eye drops applied four times daily for ten consecutive days. Mock treatment was done by using PBS as eye drop. (A.) Representative photographs of corneal
opacity examined with slit lamp microscope and graded from 0 to 4 as described in materials and methods. Corneal opacity was seen only at days 14 and 21. L-psicose treatment
significantly (*P < 0.05) inhibited the severity of corneal opacity compared to mock-treated eyes. Ten mice were used per experimental group. Each mouse was treated in their both
eyes with sugar eye drop or mock-treated in three independent experiments. Results are expressed as the mean ± SEM and are considered significant, with *P < 0.05 determined by
Student's t-test.
* 
* 
Lo
g 1
0P
FU
/m
L 
(m
ea
n
 S
E
M
) 
0
0.5
1
1.5
2
2.5
3
3.5
4
Post-treatment day 1 Post-treatment day 3
Sugar
Mock
Fig. 3. Eye swabs collected at day 1 and 3 following L-psicose treatment used for PRA in monolayer of CV-1 cells. The 200 mM concentration of L-psicose as eye drop treatment
significantly inhibited infectious virus shedding compared to mock treatment. Ten mice were used per experimental group. Each mouse was treated in their both eyes with sugar
eye drop or mock-treated in three independent experiments. Results are expressed as the mean ± SEM and are considered significant, with *P < 0.05 determined by Student's t-test.
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